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Gaucher disease (GD) is an autosomal recessive disorder caused by deficiency of 
the lysosomal hydrolase glucocerebrosidase (GBA) (EC 3.2.1.45), required for the 
degradation of glycosphingolipids. In Gaucher disease, as a result of GBA deficiency, the 
body is unable to breakdown glucocerebroside, thus allowing the accumulation of 
glucosylceramide and glucosphingosine within the lysosomal cells. The clinical 
presentation of GD consists in a multisystem disorder, and its classification of GD into its 
three subtypes is dependent primarily on the presence or absence of neurological features. 
Gaucher disease type 1 is the most common inherited genetic disease affecting Ashkenazi 
Jews, with a frequency of approximately 1 in 850 individuals having Gaucher disease and 
1 in 18 individuals being carriers. Once Gaucher disease is suspected based on clinical 
presentation, the first line of testing is measuring the glucocerebrosidase (GBA) enzyme 
activity.  
The GBA enzymatic assay has been developed as a part of this study by modifying 
the conditions described by Urban et al (2008). The process of validation was divided into 
individual steps identified to provide the most optimum conditions for the implementation 
of this assay. This assay uses the fluorometric methodology to measure the level of 
enzymatic activity. The fluorometric signal is directly proportional to the concentration of 
GBA activity in the individual being assessed. 
iv 
 
The evaluation of all components of the method validation included accuracy, 
precision, linearity, sample requirements, sample stability, and establishment of reference 
ranges. After the individual assessment of these components, it was concluded that the 
assay was successfully validated for the measurement of GBA activity, and it provides a 
valuable tool as the first line of testing for the diagnosis of Gaucher disease.  
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Lysosomal storage disorders 
Lysosomes are membrane-enclosed organelles that function as the digestive system 
of the cell by degrading intracellular materials. Lysosomal storage disorders (LSDs) are a 
heterogeneous group of defects affecting lysosome homeostasis. They are usually caused 
by the deficiency of a single hydrolase; however, they can be due to defects in lysosomal 
or nonlysosomal proteins essential to lysosomal biogenesis/function. In this group of 
disorders, more than 50 different diseases are recognized. These disorders are characterized 
by the accumulation of undigested or partially digested macromolecules, which affects 
cellular function and results in clinical abnormalities (1, 2). Taken individually most LSDs 
are rare; however, taken together, LSDs are relatively common with a cumulative incidence 
of approximately 1 in 5,000 live births (3). Moreover some disorders are found in increased 
frequency in particular populations (4).  
Laboratory investigations are critical for the diagnosis of LSD. Early diagnosis is 







Gaucher disease (GD) is an autosomal recessive disorder caused by deficiency of 
the lysosomal hydrolase glucocerebrosidase (GBA) (EC 3.2.1.45), required for the 
degradation of glycosphingolipids. Glycosphingolipids are essential components of the cell 
plasma membrane, predominantly in the nervous system. Several lysosomal storage 
disorders are caused by a deficiency in one of the steps in the glycosphingolipids catabolic 
pathway. In Gaucher disease, as a result of GBA deficiency, the body is unable to 
breakdown glucocerebroside, thus allowing the accumulation of glucosylceramide and 
glucosphingosine within the lysosomal cells. This substrate accumulation prevents cells 
within the monocyte-macrophage system to function properly (5, 6). 
The pathologic hallmark of GD is the presence of Gaucher cells in organs such as 
bone, bone marrow, liver, spleen, and lymph node parenchyma. The morphologic features 
of Gaucher cells are unique; these cells range from 20 to 100 µm in diameter and they can 
be identified by the presence of a small eccentric nuclei, and cytoplasm with crinkles and 
striation. The eccentric nuclei and the crinkles and striation found in Gaucher cells are 
caused by the abundance of lipids in the cell’s cytoplasm, resulted from the enzyme 
absence in the organism (5, 6). 
 
Clinical presentation and classification of Gaucher disease types 
The clinical presentation of GD consists in a multi-system disorder, whose features 
include peripheral blood cytopenias, hepatosplenomegaly, bone disease, and, in some 
patients, neurological manifestations (5, 7, 8). Traditionally, the classification of GD into 





Type 1 Gaucher Disease (GD1) is the most common form, and accounts for almost 
95% of GD cases among Caucasians. Its primary characteristic is the lack of central 
nervous system (CNS) involvement. The systemic features associated with this subtype 
include hepatosplenomegaly, bleeding, cytopenias, gammopathies, bone pain, avascular 
necrosis, and osteopenia. Disease development can begin any time between childhood and 
adulthood, and mild cases can remain asymptomatic. Because of widely used therapeutic 
treatment options, which include enzyme replacement therapy (ERT), substrate reduction 
therapy (SRT), orthopedic interventions, and biphosphonates for osteopenia, life 
expectancy is normal (5, 7, 8).  
Type 2 Gaucher Disease (GD2) is the most severe form of the disease. Usually 
clinical symptoms appear before one year of age with severe neurologic involvement.  GD2 
patients present developmental delay, strabismus, organomegaly, and mild pancytopenia. 
Rare cases can present with congenital ichythosis and nonimmune hydrops fetalis. Life 
expectancy is < 2 years. Because of the severe nature of the clinical symptoms, the only 
treatment available is palliative to increase the level of comfort of the patients (5, 7, 8). 
Type 3 Gaucher Disease (GD3) was formerly known as juvenile Gaucher disease, 
because the age of presentation ranges from childhood to adolescence. Its primary 
characteristic is a subacute involvement of the CNS, which is slowly progressive and it is 
characterized by developmental delay, strabismus, and cognitive regression in some 
patients. Systemic features are also present, and can include, in addition to the same 
symptoms found in GD1, growth retardation, cardiac valve calcification, and kyphosis. 




option for some patients. Most patients die in late childhood to mid adulthood (5, 7, 8). 
Gaucher disease type 1 is the most common inherited genetic disease affecting 
Ashkenazi Jews (Eastern, Central, and Northern European Jewish ancestry). In this 
population, approximately 1 in 850 individuals have Gaucher disease and 1 in 18 
individuals are carriers (9). The prevalence of GD in the general population is 1:50,000. 
The prevalence of neuropathic Gaucher disease (types 2 and 3) is low and varies among 
ethnic groups, with non-Europeans presenting higher frequency (9).    
There are over 200 known mutations responsible for the decrease or complete loss 
of function of the GBA enzyme (10).  Table 1 contains the most common mutations found 
in the GBA gene. Testing for these mutations would identify 90-95% of Gaucher disease 
cases in the Ashkenazi Jews, and 50-75% of cases in the general population. 
 
Gaucher disease diagnostic testing 
Once Gaucher disease is suspected based on clinical presentation, the first line of 
testing is measuring the glucocerebrosidase (GBA) enzyme activity (1, 2). The detection 
of very low levels of GBA can be used to diagnose patients with all subtypes of GD. The 
acceptable specimen types for the enzymatic test include dried blood spots, white blood 
cells isolated from whole blood, and cultured skin fibroblasts (1, 2, 9). The GBA enzymatic 
assay uses enzyme-specific artificial substrates, recognized and cleaved by the endogenous 
enzyme. Different substrates are available commercially that can be detected by 
fluorometric or mass spectrometry methods.  In patients lacking GBA enzymatic activity, 
the artificial substrate cannot be cleaved, and no tag is released and measured. Further 




to predict clinical outcome, since genotype-phenotype correlations have been described for 
some GBA mutations.  Moreover, molecular testing is used to identify family members that 
are carriers for the disease in at-risk families.  
 
Gaucher disease treatment options 
Enzyme replacement therapy (ERT) 
Enzyme replacement therapy works by administrating an artificially synthetized 
enzyme, which acts like the naturally occurring glucocerebrosidase enzyme, allowing the 
breakdown of accumulated glucosylceramide and glucosphingosine in the affected organs 
(11). Treatment needs to be administered throughout the patient’s life span, because the 
absence of the enzyme is corrected permanently by ERT.  
In 1991, alglucerase (Ceredase®; Genzyme, Boston, MA) was approved by the 
Food and Drug Administration (FDA) for ERT in GD patients (12). However, during 
manufacturing times, shortage of ERT drove the pharmaceutical market to expand the 
options available for GD patients. And now there are several medications available in the 
market worldwide for ERT (11-15). 
Imiglucerase (Cerezyme®; Genzyme, Boston, MA) is a recombinant DNA-
produced analogue of human glucocerebrosidade, made using Chinese hamster ovary cells, 
indicated for long-term enzyme replacement therapy for pediatric and adult patients with a 
confirmed diagnosis of Type 1 GD (13). Patients are recommended the use of this therapy 
once one or more of the following conditions are present: anemia, thrombocytopenia, bone 
disease, and hepatomegaly or splenomegaly (13). 




some amino acid differences in its composition, when comparing to the original human 
glucocerebrosidase. It is produced by genetically modifying carrot cells (14). 
Velaglucerase alfa (VPRIV®; Shire Human Genetic Therapies Inc.) was the third 
ERT approved for treatment. It is produced with human fibroblasts cell lines (15). 
Patients with GD type 1 are the most suitable targets for ERT, because these 
medications are not capable to cross the brain-barrier, thus not being able to alter the 
disease course of patients that present with central nervous system involvement. One of the 
biggest challenges that physicians face when utilizing ERT is finding the right dosage that 
works with each individual (11). In these cases, the availability of biomarkers prove 
invaluable, because they allow physicians to monitor levels of glucocerebrosidase 
byproducts present in the system, and adjust therapy on an individual basis. 
One important aspect influencing the efficacy of ERT is the age at which the 
treatment begins. Early ERT utilization is known to produce better results because it 
prevents long term complications (4).  
 
Substrate reduction therapy (SRT) 
In contrast with ERT, substrate reduction therapy’s approach acts on the glycolipid 
accumulation found in patients with GD by reducing the substrate within the cells. One of 
the advantages in SRT is its ability to be given orally, in contrast with ERT which requires 
intravenous administration. Certain patients also have contraindications to the use of ERT 
as a primary form of therapy.  
Miglustat (Zavesca®, Actelion Pharmaceuticals US) works by inhibiting the 




glycolipids (16, 17). The therapeutic use of miglustat have been limited after a large group 
of patients utilizing this therapy experienced side effects that include diarrhea, weight loss, 
abdominal distension, and tremor, and it was noted that a reduction in symptoms caused 
by the substrate accumulation took a significant longer amount of time than with the 
utilization of ERT (17). 
Eliglustat (Cerdelga®, Genzyme, Boston, MA) is a newer SRT option that is taken 
orally and is an inhibitor of the glucosylceramide synthase. It was found to have a good 
oral bioavailability, a high therapeutic index, and limited toxicity, especially when 
compared to Miglustat (18, 19). Patients can differ in their ability to metabolize eliglustat. 
Slower and poorer metabolizers retain the drug longer than patients that are ultra-rapid 
metabolizers, who need higher concentrations to achieve a similar therapeutic effect in the 
organism. Because of the different response to the drug, eliglustat requires specific 
laboratory testing to assess the patients' ability in metabolizing it (20).  
 
Gaucher disease biomarkers 
Biomarkers are measurable indicators of disease progression, and can be used to 
monitor therapeutic interventions over a period of time. A good predictor biomarker is an 
indicator whose levels are abnormal in the disease state and change upon treatment. A good 
biomarker is also specific for a particular condition. However, not all biomarkers are 
specific for one condition only. Some biomarkers are nonspecific but they can still be 
accurately used as a therapeutic tool, when combining with clinical findings and/or other 
biomarkers. 




to monitor effectiveness of treatment is fundamental not only medically but also 
financially. In most cases, the biomarkers used for therapeutic monitoring of GD will have 
a decrease in levels on the blood stream upon successful treatment. And if the reduction 
experienced upon treatment is not the level that was medically desired, physicians can use 
those results to adjust doses and try to reach the appropriate therapeutic level that the 
patient needs (21).  
 
Plasma chitotriosidase 
In healthy individuals, plasma chitotriosidase (CT) in expressed in tissue 
macrophages and secreted after activation. In GD disease patients, macrophages have 
abnormal lipid-filled cytoplasm and produce markedly elevated amounts of CT (21-23). 
Once treatment is administered, CT levels decrease according to the response from the 
patient. There is variability among patients in CT levels reached after therapy. However, 
lack of a significant decrease in CT levels may indicate the need for a revision of the initial 
therapeutic doses (6). 
About 1 in every 20 patients does not show any CT activity in plasma.  These GD 
patients require different biomarkers for therapeutic monitoring (24). 
 
Angiotensin converting enzyme 
Angiotensin converting enzyme (ACE) is a nonspecific indicator of lipid storage, 
and elevated levels reflect the accumulation of lipids in the cytoplasm of Gaucher cells 
during disease progression (25).  




disorders. However, because ACE levels decrease significantly in GD patients after starting 
treatment, the levels of ACE can be used for therapeutic monitoring in addition to other 
biomarkers. Because of its nonspecific nature, laboratory findings of ACE should be 
correlated with clinical finding (21). 
 
Tartrate-resistant acid phosphatase 
Tartrate-resistant acid phosphatase (TRAP) is an expressed marker for 
macrophages, and it is known to predict bone disease when presented in elevated levels. It 
consists of two isoforms, type 5a and 5b, both having different biochemical, clinical, and 
biological properties (26). 
TRAP is also a nonspecific biomarker for Gaucher disease (6).  It will present itself 
in high levels in untreated individuals, and decrease its value when treatment is successful.  
 
Pulmonary-and-activation-regulated chemokine 
Pulmonary-and activation-regulated chemokine (PARC-CCL18) is expressed 
predominantly by macrophages. As a biomarker for GD, PARC concentrations have been 
shown to be elevated in the serum of untreated patients, and can also be measured in urine 
because of its excretion (6, 21, 24). However, PARC is not specific only for GD patients, 
and have been elevated in the presence of other diseases as well (24). 
In contrast with chitotriosidase, whose presence cannot be detected in a percentage 
of the population, PARC can always be detected. And another advantage is the feasibility 
of measurement since enzyme-linked immunosorbent assay (ELISA) can be used to 






Glucosylsphingosine is a relatively new biomarker for Gaucher disease. Its 
usefulness is still undergoing investigation. Studies suggest that high levels of 
glucosylsphingosine will accumulate in brain tissues of Gaucher patients, especially in 
patients of type 2 and type 3 GD, where there is CNS involvement (27, 28).  
The advantage of this biomarker, comparing to previously used ones, is the ability 
to predict disease development in patients where there is neurological involvement. It is 
also proposed that this biomarker, present in high levels, may contribute to disease 
development in the bones. It will interfere with normal osteoblast function, and therefore 
causes low bone mineral density, which in turns affects bone health (28). 
11 
 














c.84G>GG NA 1035 NA Severe Very Common Null Null 
NA G>A IVS2+1 1067 NA Severe Common Null Null 
c.1226A>G 370 5841 Asn → Ser Mild 
Very 
Common ↓ Activity Stable 
c.1297G>T 394 5912 Val → Leu Severe Common ↓ Activity Stable 
c.1342G>C 409 5957 Asp → His Severe Common ↓↓↓ Activity Unstable 
c.1448T>C 444 6433 Leu→ Pro Severe 
Very 
Common ↓↓ Activity Unstable 
c.1504C>T 463 6489 Arg → Cys Mild Common ↓ Activity Stable 
c.1604G>A 496 6883 Arg → His Very Mild 
Very 
Common ↓ Activity Stable 
 
 
 CHAPTER II 
 
MATERIAL AND METHODS 
 
Chemicals and reagents 
Protein quantification was performed using the BioRad protein assay kit II (BioRad 
Laboratories, Hercules, CA; Cat #500-0002) following the SOP in use in the biochemical 
genetic laboratory at ARUP (BCG-03-3415, Cell Lysate Preparation and Protein 
Concentration Determination by UV Spectrophotometry).  
Citric acid monohydrate granular (C6H8O7:H2O; Cat# JT0119-1) and glycine 
(CH2(NH2)COOH; Cat #97061-128) were obtained from VWR Scientific (Radnor, PA). 
Sodium carbonate, anhydrous (Na2CO3; Cat #3605-01) was obtained from JT Baker 
(Center Valley, PA), and Methylumbelliferone Sodium Salt (Cat #152475) from MP 
Biomedical (Santa Ana, CA). Phosphoric acid (Cat# 452289-50mL), Sodium phosphate, 
dibasic (Na2HPO4; ARUP Cat# 44716), Tween-20 (Cat#P2287-100ML) and Sodium 
taurocholate (Cat# T4009-250MG) were obtained from Sigma–Aldrich (St. Luis, MO).  
4-methylumbelliferyl-beta-D-glucopyranoside was obtained from Marker Gene 
Technologies (Eugene, OR; Cat#M1940) or Sigma-Aldrich (St. Luis, MO; Cat# M9766). 
Detailed description of reagent preparation is in the standard operating procedure (SOP) 





Isolation of leukocytes 
To measure GBA activity, white blood cells (leukocytes) were isolated from whole 
blood collected in three different collection tubes: Acid Citrate Dextrose (ACD; yellow 
top), ethylenediamine tetraacetic acid (EDTA; purple top), and sodium heparin (green top) 
tubes. Leukocytes were isolated from whole blood using a procedure validated in the 
biochemical genetic laboratory at ARUP (BCG-03-3416, Leukocyte Isolation from Whole 
Blood). Briefly, leukocytes are isolated by centrifugation after specific lysis of red blood 
cells with a buffer containing ammonium chloride [155 mmol/L], sodium bicarbonate [10 
mmol/L], and EDTA [0.1 mmol/L]. After centrifugation, the lysed red blood cells are 
discarded with the supernatant. This step is performed twice to minimize red blood cell 
contamination. After a final wash in saline, the leukocytes pellets were stored at ≤ - 65 ̊C 
prior to the utilization. 
 
Sample preparation and protein determination 
Leukocytes pellets were resuspended with chilled nanopure water, and cell lysis 
was performed by sonication (three 10 s 8-watts bursts) utilizing the Fisher Scientific Sonic 
Dismembrator Model 100. This procedure has been validated in the biochemical genetic 
laboratory at ARUP (BCG-03-3415, Cell Lysate Preparation and Protein Concentration 
Determination by UV Spectrophotometry). Samples are kept on ice during the entire 
process. The sonicator probe tip is washed in water between samples to avoid any sample 
contamination between different specimens. 
 Protein quantification was performed for each sonicate. This value is used when 




hour per milligram of protein. An aliquot of the leukocyte lysate is used to quantify the 
protein concentration using the Bio-Rad Protein Assay, based on the method of Bradford. 
This procedure involves the addition of an acidic dye to protein solution, and subsequent 
measurement of the absorbance. Comparison to a Bovine Serum Albumin (BSA) standard 
curve provides a relative measurement of protein concentration. The Bio-Rad Protein 
Assay was performed using the microplate assay (using the Safire2™ plate reader), read at 
a wavelength of 587 nm (according to BCG-03-3415). Six calibrators were included in the 
BSA standard curve (0 – 0.59 mg/mL). 
 
Glucocerebrosidase assay in leukocytes 
 The GBA enzymatic assay uses the synthetic fluorogenic substrate 4-
methylumbelliferyl-beta-D-glucopyranoside. The assay has been developed modifying the 
conditions described by Urban et al. (2008). The SOP validated during this project is 
detailed in the Appendix. Briefly, two duplicate reactions were prepared for each 
control/patient by combining 20 µL of cell lysate and 80µL of 4-methylumbelliferyl 
substrate in buffer (50 mM citric acid, 176 mM sodium phosphate, 0.01% Tween-20 and 
20 mM sodium taurocholate; pH 5.4) in a 96-wells plate. In each run, a duplicate blank 
was included. Samples were incubated at 37 ̊ C for 2 h using the BioRad DNAEngine® 
Peltier Thermal Cycler (PCR). At the end of the 2 h incubation, the enzyme reaction was 
stopped by adding glycine carbonate buffer (pH 10.0). After stopping the enzyme reaction, 
an aliquot of the reaction mixture was transferred from the PCR tube strips to a plate, and 
further diluted by adding more glycine carbonate buffer.  Fluorescence was read using a 





The instrument setting was: 
- Measurement mode: Fluorescence Top (number of reads: 10)  
- Gain (Manual): 49  
- Excitation (EX) 365nm 
- Emission (EM) 441nm  
- Excitation bandwidth: 10.0 nm 
- Emission bandwidth: 10.0 nm 
 
Calculations 
GBA activity was calculated for each sample measuring the reaction product (4-
methylumbelliferone) against a standard calibration curve. The calibration curve is 
established with each run. The average fluorescence reading of the duplicate reactions is 
used in the calculations, and it must be within 20% coefficient of variation (CV%). After 
subtracting the average fluorescence of the duplicate blanks, the average fluorescence 
reading is divided by the slope of the standard curve, and then multiplied by several factors 
that account for sample dilution, incubation time, and milligram of proteins used.  
Gaucher disease patients have low to almost undetectable GBA activity. Carriers 
of GBA mutations may display lower activity; however, considerable overlap exists with 
the normal range. Therefore, this test is not helpful in identifying GD carriers. 
The GBA activity is expressed in nanomoles of substrate hydrolyzed per hour per 









GBA activity = (fluor. of activity – fluor. of blank) * 0.24 *6.25 ÷ 2 ÷ (mg of protein used for 





Note: The above calculations are based upon: 
          * 0.24 = correction to account for final concentration in samples versus calibrators 
          * 6.25 = correction for final volume  
          / 2 = correction of 120 min to 60 min  
           mg of protein used for assay = 0.020*protein conc. of sonicate (mg/mL) 
      y = slope of the standard calibration curve  
 
Characteristics of known Gaucher disease patients used in the clinical 
sensitivity/specificity study 
For this study, whole blood samples were collected from a cohort of five Gaucher 
disease patients. All five patients are followed at the Metabolic Clinic at the University of 
Utah, under the supervision of Dr. Nicola Longo, Chief of the Division of Medical 
Genetics, Professor of Pediatrics, and Adjunct Professor of Pathology at the University of 
Utah. For the sample collection, an informed consent was obtained by all patients. 
Demographic, clinical, and laboratory data were obtained by retrospective chart review. 
This study was reviewed and approved by the Institutional Review Board at the University 
of Utah. Table 2 summarizes the clinical features of the five GD patients.  





diagnosis was 15.8±7.7 years. In all cases, the diagnosis was confirmed by DNA 
sequencing of the GBA gene (Table 3). All patients are currently on enzyme replacement 
treatment (biweekly), and have been for several years. For this study, we did not have 














Onset DX Current 
A M 8 12 37 Hepatosplenomegaly 






mobility; severe pain 
 




mobility; mild pain 
 
C M UNK 9 45 Hepatosplenomegaly 












unrestricted mobility; mild 
pain 
 
E M UNK 29 45 Bone disease (mild) ERT 
(biweekly) 
Normal development; 
unrestricted mobility; mild 
pain 




Table 3.  Molecular characterization of Gaucher disease patients. 
 GBA gene mutations 
Patient Allele 1 Allele 2 
A c.1226A>G (p.N370S) IVS2+1G>Aa 
B c.1226A>G (p.N370S) c.1448T>C (p.L444P) 
C c.1226A>G (p.N370S) c.644C>A (p.A215D) 
D c.1226A>G (p.N370S) IVS8+1G>Tb 
E c.1226A>G (p.N370S) c.1226A>G (p.N370S) 
a Pathogenic mutation (impaired splicing). b Unpublished mutation, likely 
pathogenic (impaired splicing).  
 
 





 The main aim for this project was to develop and validate an enzymatic assay to 
measure the activity of the lysosomal enzyme glucocerebrosidase (or acid β-glucosidase, 
EC 3.2.1.45) in leukocytes for the diagnosis of Gaucher disease. To develop the assay and 
validate it for the use in the biochemical genetic laboratory at ARUP, the conditions 
described in Urban et al. (2008) were used with minor modifications. 
 
Effects of commercial substrate used 
 This enzymatic assay uses the synthetic fluorogenic substrate 4-
methylumbelliferyl-beta-D-glucopyranoside. The assay combines leukocyte lysate with 
the substrate prepared in buffer. We tested the 4-methylumbelliferyl-beta-D-
glucopyranoside produced by two companies: Marker Gene Technologies (Eugene, OR; 
Cat#M1940) and Sigma-Aldrich (St. Luis, MO; Cat# M9766). Four leukocyte lysates were 
tested using the two different substrates, three obtained from healthy controls and one from 
a GD patient (patient E; see Table 2). All patients were run in duplicate. A duplicate blank 
was run with each substrate. Table 4 shows the average fluorescence detected in the blank 




 The background noise, due to the non-enzymatic breakage of 4-
methylumbelliferyl-beta-D-glucopyranoside, was present in the blank assayed with both 
substrates; however, the background was much higher using the Marker Gene 
Technologies (company 1) substrate. There was a difference in GBA activity between 
controls and the GD patient, with the GD patient presenting a markedly decreased activity 
compared to the controls. However, with the Marker Gene Technologies (company 1) 
substrate the GBA activity in the GD patient was 9% of the controls average while it was 
4% using the Sigma-Aldrich substrate (company 2). Because of the modest background 
and the better discrimination between controls and patient, we elected to use the Sigma-
Aldrich substrate for the assay validation.   
 
Effects of sodium taurocholate concentration 
   GBA requires interaction with negatively charged lipids and the cofactor saposin C 
for optimal activity.  Detergents (like Tween-20) and negatively charged bile salts (such as 
sodium taurocholate, TA) allow for optimal GBA activity at acidic pH (buffer pH = 5.4) 
in vitro. We tested two sodium taurocholate concentrations: 10mM and 20mM. Four 
leukocyte lysates were tested using the two different buffers, three obtained from healthy 
controls and one from a GD patient (patient E; see Table 2). All patients were run in 
duplicate.  
 Table 5 shows the average fluorescence detected in the blank and in the lysates, and 
the corresponding GBA activity using the Sigma-Aldrich substrate. The background noise 
in the blank was similar with either concentration. GBA activity in the GD patient was 




higher sodium taurocholate concentration; although the experiment was not repeated. We 
elected to use bGLU-PC buffer with 20mM sodium taurocholate for the assay validation. 
 
Calibration curve 
   The calibration curve is prepared shortly before reading the plate by diluting the 
standard working solution in Glycine Carbonate Buffer. An example of the calibration 
curve built using the average readings among 8 different standard curves (mean ±SD) is 
presented in Figure 1. The theoretical concentrations: 0, 0.12, 0.52, 1.03, 2.0 and 
2.53nmol/mL are on the x-axis, while the respective readings by the instrument at the fixed 
wavelength (365.0/441.0nm) are on the y-axis (RFU = relative fluorescence units). The 
curve is forced through the zero. The regression line is determined by excel via least 
squares method (1st order). The slope of the regression is used in the calculations of the 
GBA activity; inter-assay variability of the slope within the 8 experiments had a coefficient 
of variation (CV%) <15%.  
 
Specimen type 
The effect on GBA activity of the anticoagulant used in the blood collection tubes 
was evaluated by testing three different collection tubes. Blood from three healthy controls 
was collected in Acid Citrate Dextrose (ACD; yellow top), ethylenediamine tetraacetic acid 
(EDTA; purple top), and sodium heparin (green top) tubes, and processed at the same time.  
The anticoagulant used in the blood collection tubes seems to affect GBA activity. 
Samples collected using heparin tubes display lower activity, markedly reduced in two 




compared to the ACD tubes in two controls, and mildly reduced in one (Table 6). Based 
on these results, ACD tubes and EDTA tubes are both accepted as blood collection tubes. 
Validation experiments were performed using both ACD tubes and EDTA tubes, 
depending on sample availability. The normal ranges include results obtained with both 
sample types.  
 
Specimen stability 
Stability of the whole blood prior to the white blood cells isolation was evaluated 
by storing blood samples at room temperature up to 3 days from collection. Leukocytes 
were isolated at time 0, 2, and 3 days, and GBA activity was evaluated. Whole blood was 
collected from two healthy controls (a 25-year old male [25M] and a 37-year old female 
[37F]), in ACD tubes. The T0 point was immediately processed, while the other two tubes 
were processed at 2 and 3 days post blood draw, after being stored at room temperature. 
All cell pellets were stored at -65 ̊C prior to sample analysis. GBA activity was evaluated 
in all samples in the same experiment, using lysates prepared that day from the pellets. We 
observed a decrease in enzymatic activity after two days, but GBA activity did not change 
between day 2 and day 3 (Table 7). We concluded that samples received in the lab were 
acceptable up to 3 days from collection. However, further experiments are needed to 
evaluate stability after 3 days, as well as to verify the dramatic drop in GBA activity 
between the T0 and T2 more samples need to be analyzed.  
 To assess the leukocyte lysates stability once the pellet has been sonicated and upon 
storage at -65°C, we evaluated GBA activity in one normal sample that was sonicated, and 




control for each of the validation runs. We had a total of 10 values from 8 independent 
experiments over an eight-month period. The mean ±SD activity was 6.7±1.3 nmols/h/mg 
protein, the CV% was 19%, which is in line with the inter-assay imprecision observed (see 




To assess the accuracy of the assay, GBA activity was measured in three 
proficiency testing specimens obtained from ERNDIM (European Research Network for 
Evaluation and Improvement of Screening, Diagnosis and Treatment of Inherited 
Disorders of Metabolism), as part of the lysosomal enzymes scheme. Samples were tested 
after at least a freeze/thaw cycle, after they were used for proficiency testing for other 
assays currently in use in the biochemical genetic laboratory at ARUP.  
These proficiency samples were lyophilized fibroblasts, which were reconstituted 
in water prior to the analysis and quantified. The results were compared to the other 
participant laboratories (Table 8). All samples displayed normal GBA activity. The CV% 
between our result and the average result of all participating labs was less than 10% for all 
samples. 
 Additionally, to test the effect of lower protein concentration, we measured the 
accuracy of the assay using different dilutions of the same sample. GBA activity was 
measured in two normal leukocyte samples (collected in ACD tubes; from a 43- and a 55-
year old female) in triplicate at three different protein concentrations (1X, 2X, and 10X 




 Table 9 and 10 show the intra- and inter-assay variability at three different protein 
concentrations. GBA activity was linear within a broad range of protein concentrations: 
1.82 - 0.11 mg/mL.  
 The intra-assay variation was ≤ 20% at all concentrations (2.8 - 11.6%) with a recovery 
of 100%±10%. The inter-assay variability was ≤ 20% at all concentrations for leukocyte 2, 
but leukocyte 1’s variability was 23% at the lowest concentration (0.18mg/mL). However, 
recovery was 100%±10% at all concentrations. 
 
Precision 
The intra- and inter-assay variation in GBA activity was evaluated in leukocyte 
samples obtained from a normal control (from a 26-year old female) and from a Gaucher 
disease patient (patient A; see Table 2). Samples were isolated from whole blood samples 
collected in EDTA tubes (purple top), and stored at -65°C prior to the analysis. Each sample 
was assessed three times within a sample run, and in three different experiments (Table 
11A and B). All reactions were run in duplicate.  
The intra- and inter-assay variation in GBA activity was ≤ 20% in the normal 
control (Table 11A). The fluorescence detected in the GD patient was low (52 – 80 RFU), 
and within the blank average 62.7±22.9 (see interference section below). The variability 
was much higher in the GD patient sample where GBA activity is markedly reduced, 








To define the normal reference range for GBA activity in leukocytes, we evaluated 
enzyme activity in 32 normal samples. All leukocyte samples used to determine the normal 
range were extracted from whole blood samples collected in ACD or EDTA tubes, and 
processed according to the SOP. Cell pellets were stored at -65°C prior to the analysis. 16 
samples were collected from healthy donors, and 16 samples were clinical samples sent to 
the biochemical genetic laboratory for unrelated testing, and de-identified according to 
ARUP procedures. Carrier status for Gaucher disease cannot be excluded in this cohort, 
since molecular testing was not performed. The mean activity was 11.94 nmol/h/mg protein 
(± 4.48 standard deviation).  
The reference interval was established utilizing the software EP Evaluator (Release 
10; Data Innovations) using the parametric analysis (Figure 2) with a confidence ratio > 
0.26. Figure 2 showed the distribution of the GBA activity normal values (N = 32). Based 
on this distribution, the normal range is 3.7 – 21 nmol/hr/mg protein.  
 
Interferences 
 In each experiment, a blank was run in duplicate to determine the background 
fluorescence in the assay buffer.   The duplicate blanks contain water, and are incubated in 
the assay buffer together with controls and samples. All reactions are stopped by glycine 
carbonate buffer. The calibrator 1 in the standard calibration curve assesses the background 
fluorescence in the stopping buffer. Neither displays a significant fluorescence. Over 
approximately eight months, including all experiments run for this validation, the mean 
fluorescence ± SD of the blank was 62.7±22.9 (N = 8), CV% = 36.6%, less than 0.5% the 




calibrator 1 (0 nmol) was 11.6±6.9 (N = 8), CV% = 59.3%, less than 0.1% the average 
value for the highest calibrator (2.53 nmol). 
 
Clinical significance 
 All samples collected from healthy donors or sent to our clinical lab for unrelated 
testing displayed GBA activity.  Although carrier status for Gaucher disease cannot be 
excluded in this population since molecular testing was not performed.  
We had access to leukocytes from five Gaucher disease patients on biweekly 
enzyme replacement therapy.  GBA activity was markedly reduced in all five samples, and 
outside the normal range (Table 12). All these patients have been on ERT for several years; 




Table 4. Average fluorescence and GBA activity in the blank, a GD patient (patient E; see 
Table 2) and three healthy controls using 4-methylumbelliferyl-beta-D-glucopyranoside 
produced by Marker Gene Technologies (company 1) or Sigma-Aldrich (company 2).  
 
 Fluorescence (RFU) GBA Activity (nmol/h/mg) 
 Company 1 Company 2 Company 1 Company 2 
Blank 701.5 72.0 0 0 
GD patient 761.0 112.5 1.2 0.5 
Control 1 1361.5 1503.0 11.8 18.1 
Control 2 1787.0 1489.0 12.9 12.4 
Control 3 2209.0 1008.0 15.5 7.1 
Units: fluorescence expressed in relative fluorescence units; GBA activity expressed in 







Table 5. Average fluorescence and GBA activity in the blank, a GD patient (patient E) and 
three healthy controls using bGLU-PC buffer with 20mM or 10mM sodium taurocholate.  
 
 Fluorescence (RFU) GBA Activity (nmol/h/mg) 
 20mM TA 10mM TA 20mM TA 10mM TA 
Blank 72.0 77.0 0.0 0.0 
GD patient 112.5 191.0 0.5 1.6 
Control 1 1503.0 1464.5 18.1 17.6 
Control 2 1489.0 1424.0 12.4 11.8 
Control 3 1008.0 959.5 7.1 6.7 
Units: fluorescence expressed in relative fluorescence units; GBA activity expressed in 




Table 6. Variability in GBA activity due to sample type.  
  GBA Activity (nmol/h/mg)  
 ACD EDTA Heparin CV % 
Control 1 13.4 12.9 12.8 2.3% 
Control 2 11.4 11.6 6.0 33.1% 
Control 3 13.7 7.5 6.8 41.0% 
Units: GBA activity expressed in nanomoles of substrate hydrolyzed per hour per 




Table 7. Variability in GBA activity due to sample stability. The cumulative CV% of the 
results obtained with the three collection tubes is indicated.  
 
  GBA Activity (nmol/h/mg)  
 T0 T2 T3 CV % 
25M 12.0 4.9 5.3 53.9% 
37F 7.4 4.7 4.3 30.8% 
Units: GBA activity expressed in nanomoles of substrate hydrolyzed per hour per 






Table 8. Glucocerebrosidase activity in three proficiency samples. Results were compared 
to the mean of participant labs. N indicated the number of participants.  
 
  GBA Activity (nmol/h/mg)  
ERNDIM 
sample N All labs Your lab CV % 
2015.01 58 248.0 241.7 1.8% 
2015.03 61 143.0 154.5 5.5% 
2015.04 62 336.0 374.7 7.7% 




Table 9. Effect of low protein concentrations on the GBA activity (Normal leukocyte 1) 
  Normal Leukocytes 1  
 Intra-assay  Inter-assay  
Proteins 
[mg/mL] 
Fluor GBA  Fluor GBA  
Mean   Mean   
1.84 
1 2430 7.9  2430 7.9  
2 2220 7.2  2181 10.3  
3 2207 7.2  2838 9.3  
Average   7.4   9.2  
CV%   5.6% Recovery  13.0% Recovery 
0.92 
1 1112 3.5 100.8% 1112 3.5 92.5% 
2 1168 3.7  1110 5.1  
3 1235 4.0  1281 4.0  
Average   3.7   4.2  
CV%   5.4% Recovery  19.0% Recovery 
0.18 
1 251 0.7 107.9% 251 0.7 103.0% 
2 290 0.8  275 1.1  
3 306 0.9  386 1.0  
Average   0.8   0.9  
CV%   11.6%   23.0%  
Units: fluorescence expressed in relative fluorescence units; GBA activity expressed in 














Table 10. Effect of low protein concentrations on the GBA activity (Normal leukocyte 2) 
  Normal Leukocytes 2  
 Intra-assay  Inter-assay  
Proteins 
[mg/mL] 
Fluor GBA  Fluor GBA  
Mean   Mean   
1.14 
1 2035 10.4  2035 10.4  
2 1882 9.6  2113 15.6  
3 1897 9.6  2555 13.0  
Average   9.9   13.0  
CV%   4.4% Recovery  20.0% Recovery 
0.57 
1 1014 5.1 103.1% 1014 5.1 96.8% 
2 1048 5.2  1011 7.3  
3 993 4.9  1321 6.5  
Average   5.1   6.3  
CV%   2.8% Recovery  18.0% Recovery 
0.11 
1 235 1.0 105.0% 235 1.0 99.0% 
2 236 1.0  217 1.3  
3 248 1.1  376 1.5  
Average   1.0   1.3  
CV%   3.6%   20.0%  
Units: fluorescence expressed in relative fluorescence units; GBA activity expressed in 



























Table 11. Intra- and inter-assay variation in leukocytes from a normal control (A) and from 
a GD patient (patient A) (B) 
 
A  Normal Leukocytes  
 Intra-assay  Inter-assay  
Proteins 
[mg/mL] 
Fluor GBA  Fluor GBA  
Mean   Mean   
0.63 
1 1369 11.8  1369 11.8  
2 1409 12.2  1631 12.9  
3 1413 12.2  1130 11.6  
Average   12.1   12.1  
CV%   1.8%   5.8%  
 
B 
 GD patient Leukocytes  
 Intra-assay  Inter-assay  
Proteins 
[mg/mL] 
Fluor GBA  Fluor GBA  
Mean   Mean   
0.46 
1 70 0.1  70 0.1  
2 79 0.2  80 0.5  
3 74 0.1  52 0.2  
Average   0.1   0.2  
CV%   43.5%   90.8%  
Units: fluorescence expressed in relative fluorescence units; GBA activity expressed in 




Table 12. GBA activity in five GD patients. Normal range: 3.7 – 21 nmol/h/mg protein 
 
Units: GBA activity expressed in nanomoles of substrate hydrolyzed per hour per 
milligram of protein 
 
 Gender Age (years) Collection tube 
Storage  
(days at RT) GBA activity 
A M 37 EDTA 1 0.1 
B F 61 EDTA 2 1.4 
C M 45 EDTA 1 0.7 
D F 34 EDTA 1 0.2 





Figure 1. Standard calibration curve. The coefficient of variation (CV%) is indicated for 













































Calibrators Mean SD CV%
0 11.6 6.9 59.3%
0.12 1200.4 361.2 30.1%
0.52 3383.8 485.0 14.3%
1.03 6537.7 1054.1 16.1%
2 12282.1 1629.7 13.3%
2.53 14887.4 1961.9 13.2%
R² 0.9937 0.0 0.5%
R 0.9969 0.0 0.2%
Blanks 62.7 22.9 36.6%
Slope 6032.9 784.5 13.0%




Gaucher disease (GD) is an autosomal recessive disorder caused by deficiency of 
the lysosomal hydrolase glucocerebrosidase (GBA) (EC 3.2.1.45), required for the 
degradation of glycosphingolipids. GD is a multisystem disorder, whose features include 
peripheral blood cytopenias, hepatosplenomegaly, bone disease, and, in some patients, 
neurological manifestations (5, 7, 8). Patients with the less severe form of the disease (GD 
type I) benefit greatly from therapeutic intervention, which include enzyme replacement 
therapy. Because of improved clinical outcome after treatment, diagnosing GD patients is 
critical. The detection of very low levels of GBA enzyme activity can be used to diagnose 
GD. In this study, we aimed to develop and validate an enzymatic assay for use in the 
Biochemical Genetics Laboratory, which is part of ARUP Laboratories.  
The GBA enzymatic assay has been developed modifying the conditions described 
by Urban et al. (2008). During test development, the optimum conditions for the assay were 
established. Chemical nonenzymatic breakage of the 4MU substrates can be a problem for 
enzymatic assays fluorescence-based because of high background in the blank. The 
commercial substrate obtained from Sigma-Aldridge displayed less background and was 
chosen for the assay validation. Moreover, we evaluated the effects of the anticoagulant 




tested Acid Citrate Dextrose (ACD; yellow top), ethylenediamine tetraacetic acid (EDTA; 
purple top), and sodium heparin (green top) tubes. In three normal controls, GBA activity 
was similar in ACD tubes and EDTA tubes and these sample types were considered 
acceptable as blood collection tubes. Reference ranges were established using samples 
collected in ACD and EDTA tubes. Because of the difference in GBA activity obtained 
using heparin tubes, further investigation is necessary to define a normal range to use for 
this sample type. Differences in enzymatic activity among different collection tubes have 
been previously observed in the biochemical lab during several validations for lysosomal 
enzymatic assays. Moreover, acceptability criteria that include or exclude sample types are 
usually published by laboratory to aid the users’ test submission. 
During method validation, we assessed accuracy, precision, and linearity of the 
assay. The method was adequately reproducible, with good intra and interprecision within 
the linearity range (1.82 - 0.11 mg/mL), and good accuracy. One important limitation of 
our study was the fact that we only had access to three proficiency-testing samples. The 
ERNDIM lysosomal enzymes scheme only provides eight samples each year for testing, 
and our use was further limited by the clinical lab need for these samples.   
The clinical sensitivity and specificity of the assay was evaluated by testing normal 
controls and five GD patients. All samples collected from healthy donors or sent to our 
clinical lab for unrelated testing display GBA activity in the range previously reported (9). 
In patients lacking GBA enzymatic activity, the artificial substrate (4-MUF) cannot be 
cleaved, and thus no fluorescence is released. Both the fluorescence detected and GBA 
activity calculated were low in all five GD patients tested, and significantly different than 




and GBA deficient patients. Because of the significant decrease in GBA activity, enzymatic 
activity measurements in GD patients may fall below the linearity range of the assay. 
Acceptability criteria for precision in these cases would be mean ± 0.5 nmol/h/mg protein. 
Table 11B clearly shows that precision can be affected when testing GD leukocytes, if 
activity is outside linearity: < 1 nmol/h/mg protein (normal range: 3.7 – 21). In these 
patients, activity will be reported as less than 1 nmol/h/mg protein, and considered 
consistent with Gaucher disease.  
In conclusion, the enzymatic assay to test for GBA deficiency was successfully 
validated and can be used for the measurement of GBA activity both in GD patients as well 
as normal patients. 
 
 APPENDIX A 
 
BETA-GLUCOSIDASE ACTIVITY IN LEUKOCYTES STANDARD  
OPERATING PROCEDURE 
 




This assay is designed to measure the activity of the lysosomal enzyme β-glucosidase 
(also known as acid β-glucocerebrosidase, GBA; EC 3.2.1.45) in leukocytes to aid the 




  The lysosomal enzyme β-glucosidase catalyzes the breakdown of the glycolipid 
glucosylceramide (GlcCer) to ceramide and glucose. The deficiency of this enzyme 
causes Gaucher disease (OMIM 608013). The pathologic hallmark of GD is the presence 
of Gaucher cells in organs such as bone, bone marrow, liver, spleen, and lymph node 
parenchyma. The clinical presentation of GD consists in the presence of a multi-system 
disorder, whose features include peripheral blood cytopenias, hepatosplenomegaly, bone 
disease, and, in some patients, neurological manifestations.  Traditionally, the 
classification of GD into its three sub-types (type I, type II and type III) is dependent 
primarily on the presence or absence of neurological features. Type 1 GD (GD1) is the 
most common form, and accounts for almost 95% of GD cases among Caucasians. Its 
primary characteristic is the lack of central nervous system (CNS) involvement. 
  This enzymatic assay uses the synthetic fluorogenic substrate 4-methylumbelliferyl-
beta-D-glucopyranoside. The assay combines leukocyte lysate with the 4-
methylumbelliferyl substrate prepared in buffer (50 mM citric acid, 176 mM sodium 
phosphate, 0.01% Tween-20 and 10 mM sodium taurocholate; pH 5.4). Samples are 
incubated at 37°C for 2 hours. The enzyme reaction is stopped by adding glycine 




4-methylumbelliferone standard curve.  In the absence of the enzyme, the artificial 




This procedure is performed by a Technologist trainee, Technologist I, II or Medical 
Technologist in the Biochemical Genetics Laboratory. Results and run data, including all 
QC and other test parameters, are reviewed and approved (validated) by a Medical 
Technologist or Technologist II with 6 years of experience, or by a Medical Director. In 
urgent situations, a less experienced individual may validate the run, provided that an 
individual with appropriate experience also reviews and validates the data on the next 
shift that such a person is available. Once the run is validated, patient results may be 
verified in the LIS (released to clients) by the Technical Supervisor, Lead, or any 




CORP-PROC-7108, pH Meter Use and Maintenance  
Safire2™ Plate Reader User Manual (version 1.5; 2005-12; Tecan) 
Safire2™ Plate Reader Use and Maintenance 
BioRad DNAEngine® Peltier Thermal Cycler (PCR) Use and Maintenance 
BCG-03-3416, Leukocyte Isolation from Whole Blood 
BCG-03-3415, Cell Lysate Preparation and Protein Concentration Determination by UV 
Spectrophotometry 
CORP-PROC-7108, pH Meter Use and Maintenance 
CORP-PROC-7073, Specimen Handling: Ordering and Viewing Except Tests 
 
Personal Protective Equipment (PPE) 
 
Performance of this procedure will expose testing personnel to potentially bio-hazardous 
material and possible chemical hazards. All specimens must be handled as potentially 
infectious material as outlined in the ARUP safety manual. 
The reagent(s) and/or chemical(s) that are used in this assay may be hazardous to your 
health if handled incorrectly. A brief listing of precautions for each chemical hazard is 
included in the reagent section of this procedure. 
 
More extensive information concerning the safe handling of the reagents and/or 
chemicals used in this assay, as well as other important safety information, may be 
obtained by consulting the Safety Data Sheet (SDS) and HAZ-COM manual, and ARUP 
safety manual. Before performing any part of this assay, the technologist must take any 





This procedure may expose the user to: 
 Bloodborne pathogens 
 Hazardous reagents 
 
To perform this procedure the user must wear: 
 Gloves 
 Safety glasses, Face shield or equivalent 
 Fully buttoned laboratory coat 
 
To perform this procedure the user must use: 
 Fume hood 
 Disinfectant following procedure: 
  Diluted Bleach (10% solution) 
  Commercial disinfectant 
 
Specimen 
1. Specimen: Whole blood 
 
2. Specimen Collection:  
Collect 3-5mL of whole blood in glass blood collection tube (1 mL is the 
minimum volume necessary to attempt the isolation of white blood cells). 
However, physiological variation in white cell count will influence the minimum 
amount of sample necessary for the extraction.  
• Acid Citrate Dextrose (ACD, Solution A or B) (yellow top) tubes are preferred; 
EDTA (purple top) tubes are accepted. 
 
3. Specimen storage and transportation: 
i. The specimen should be stored refrigerated for transport, 
ii. Room temperature whole blood samples are acceptable. A disclaimer may be 
necessary (refer to specific enzymatic assay SOP for accepted samples).  
iii. Whole blood samples (ambient or refrigerated) need to arrive within 3 days 
from collection. 
 
4. Suboptimal specimens: The medical director will determine whether a suboptimal 
specimen will be analyzed and whether the results will require a disclaimer. An 
‘except test’ should be ordered to obtain approval from the client before reporting 
any results that require a disclaimer. Refer to CORP-PROC-7073, Specimen 






5. Unacceptable specimens: 
i. Blood sample that has been frozen. 
ii.  Whole blood received after 3 days from collection 
iii. Sodium Heparin (green top) tubes, tubes containing no anticoagulant (plain 
red top) and serum separator tubes (SST) are NOT accepted. 
iv Grossly hemolyzed blood. 
 
6. Sample Stability: 
Blood samples are acceptable for up to 3 days from the date of the draw. 
 
Known Interferences 
No known interferences have been described.  
 
Reagents and Chemicals 
NOTE: If no expiration date is provided by the manufacturer, label the vial with an 
expiration date of 5 years from the date opened. 
 
1. BioRad protein assay kit II. BioRad Laboratories. Cat #500-0002 
a. BioRad Protein Assay Standard II–Bovine Serum Albumin (BSA). Store -20ºC. 
b. BioRad Protein Assay Dye Reagent Concentrate. Store 2-8 ºC. 
2. Citric acid, monohydrate granular (C6H8O7:H2O), MW 210.14 VWR Scientific. 
Cat# JT0119-1.  Store at ambient temperature. 
3. Glycine (CH2(NH2)COOH), MW 75.07 VWR Scientific. Cat #97061-128.  Store 
at ambient temperature. 
4. Phosphoric acid. Sigma Cat# 452289-50mL. Store at room temperature in cabinet 
designed for only acids. Stable until expiration date or for two years from the date 
opened. 
5. Methylumbelliferone Sodium Salt, MW 198.15 MP Biomedical. Cat #152475. 
Store at ambient temperature. 
6. Methylumbelliferyl-beta-D-glucopyranoside MW 338.31. Sigma. Cat# M9766. 
Store at -20 ºC or below. 
7. Sodium carbonate, anhydrous (Na2CO3) MW 105.9 JT Baker. Cat #3605-01.  
Store at room temperature. 
8. Sodium phosphate, dibasic (Na2HPO4) MW 141.96 Sigma-Aldrich. ARUP# 
44716.  Store at ambient temperature 
9. Sodium taurocholate MW 537.68 Sigma-Aldrich. Cat# T4009-250MG. 




Reagents Prepared In-House 
1. Chilled Clinical Laboratory Reagent Water (CLRW). 
a. CLRW is produced by a CLRW purification system fed by a deionized water 
source. 
b. Store at 2-4ºC up to 24 hours. 
2.  Phosphate Citrate Buffer for beta-glucosidase assay (bGLU-PC buffer) 
a. Dissolve 5 g sodium phosphate (176 mmol/L) and 2.1g of citric acid (50 
mmol/L) in 150mL of Nanopure water. 
b. Adjust to pH 5.4 with phosphoric acid. 
 c. Add 2 mL of Tween-20 and 1.07 g of sodium taurocholate. 
d. Adjust the volume to 200mL with Nanopure water. 
e. Store in brown glass bottle refrigerated (2-4ºC) up to one year. 
5. Glycine Carbonate Buffer (Alternatively, obtained Glycine Buffer from 
Reagent Lab Item #G-11060.) 
 a. Dissolve 12.8g glycine (0.17mol/L) and 18.0g sodium carbonate (0.17mol/L) 
in 800mL of Nanopure water. 
 b. Adjust the pH to 10.0 with 6M NaOH.  
 c. Bring to final volume of 1000mL. 
d. Store in brown glass bottle at ambient temperature up to one year.  
6. 4-Methylumbelliferone Standard Stock (1mmol) – Prepare in Amber bottle to protect 
from light 
a. Dissolve 3.96 mg of 4-methylumbelliferone in 19mL of Glycine Carbonate 
Buffer. 
b. Place on a stir plate 1 hour to thoroughly mix the reagent.  Sonicate for 5 minutes 
prior to the 1 hour to help get the reagent into solution. 
c. After powder is dissolved, bring final volume up to 20mL. 
d. Store in brown glass bottle refrigerated (2-4ºC) up to 4 months.  
7. 4-Methylumbelliferone Standard Working Solution (0.1mmol) 
a. Dilute 1 mL of 4-Methylumbelliferone Standard Stock (1mmol) in 9mL of 
Glycine Carbonate Buffer. 
b. Store in brown glass bottle refrigerated (2-4ºC) up to 4 months. 
8. Methylumbelliferyl-beta-D-glucopyranoside  (4-MUF) substrate 
a. The 4-MUF substrate must be freshly prepared each time.   
b. Dissolve the 4-MUF substrate in bGLU-PC buffer. Add 1.7mg (± 0.02) (5.0 mM) 
for each mL of substrate prepared. 1.6mL of substrate are required to run 6 
samples (including blanks and controls): add 2.72 (± 0.06) of 4-MUF to 1.6 mL of 
bGLU-PC buffer. 
c. Sonicate for 10-30 seconds to dissolve if necessary. 






1. Prepare standard curve using the 4-Methylumbelliferone Standard Working 
Solution (0.1mmol) and add to the plate before reading samples.   
  According to the table, below, pipette the appropriate amount (µL) of 4-
methylumbelliferone Standard Working Solution (0.1mmol) into a tube designated 
for each level. 
 
Calibrators µL of 4-Methylumbelliferone Standard Working Solution 
Final concentration 
µmol/L 
1 0 0 
2 3 0.12 
3 13 0.52 
4 26 1.03 
5 54 2.0 
6 65 2.53 
 
2. Add 2.5mL of the GC buffer to each tube quickly.  Use the bottle top dispenser set at 
2.5 mL.  Add the buffer directly into the tube.  Be gentle but firm in adding the 
buffer, so that the calibrator will be properly mixed. 
Acceptance criteria: Standard 1 (calibration blank) reading < 50.  Slope range should 
be evaluated when a new 4-methylumbelliferone Standard Working Solution is 
prepared. Slope range should be within mean slope ± 15%. Five replicates of the new 
standard curve should be read to establish the mean slope. Mean slope for the new 
standard should be compare to old slope, and be within ± 20%. 
 
Control Samples 
1. Control samples (normal and affected) are obtained from patient samples that were 
assayed for beta-glucosidase activity or healthy donors after IRB approval.  See 
procedure below.  Patient samples are de-identified according to ARUP protocols. 
2. 75µL of the control sample (isolated leukocytes after sonication) is aliquoted into 
0.5mL microcentrifuge tubes. 
3. The microcentrifuge tubes are frozen at ≤-65°C for up to five years. 
4. Control ranges are established evaluating the mean ± SD from at least 10 – 15 
independent experiments.  
5. If sample from an affected individual is not available, a normal sample can be used 




6. Alternatively, cultured fibroblasts from Gaucher disease patients can be used. The 
fibroblast pellet is re-suspended in water, and after sonication 75µL of the sample is 
aliquoted into 0.5mL microcentrifuge tubes. The microcentrifuge tubes are frozen at 
≤-65°C for up to five years. 
 
Equipment and Supplies 
Laboratory Supplies 
1. 13x75 Culture tubes, disposable, plastic (Sarstedt Cat#12860) ARUP Item #13652.  
2. 96-well microplate for fluorescence, black, flat bottom. (VWR Cat#29442-070) 
ARUP Item#49998. 
3. 96-well microplate, non-sterile, clear, flat bottom. (VWR Cat#29442-070) ARUP 
Item # 51701. 
4. Adjustable volume pipettes and tips. 
5. CoolRack® XT PCR96 (VWR Cat#89239-428) 
6. Ice bucket with ice. 
7. Microcentrifuge tubes, disposable (1.5mL) (VWR Cat#89000-028) ARUP Item 
#32863. 
8. Microcentrifuge tubes, disposable (0.5mL) (VWR Cat#14231-060) ARUP Item 
#46212. 
9. Microtubes. VWR Cat #211-0092. 
10. PCR 8-Well Tube Strips. (VWR Cat #20170-004) ARUP Item #47813. 
11. PCR 8-Well Tube Bubble Caps. (VWR Cat #20170-004) ARUP Item #47812. 
12. Volumetric flasks (1000mL, 500ml, 100mL, 10mL).  
 
Instruments and Consumables 
1. BioRad DNAEngine® Peltier Thermal Cycler (PCR) 
2. Eppendorf table top centrifuge 5417C. 
3. Fisher Scientific Sonic Dismembrator Model 100. 
4. Tecan Safire2™ 4-monochromator scanning fluorescence plate reader.  
 
Records Required and Retention 
Records are retained as described in the ARUP Corporate Record Retention Policy 
(CORP-POLICY-0160) which is in agreement with the Integrated Oncology and 
Genetics Division Record Retention Policy, IOG-01-1000 (generally 25 years for patient 
records).  All work lists, run records, patient results, related documents, QC reports, and 




are kept on file in the laboratory for a minimum of two months (space permitting) and 
then may be transferred to an off-site storage.  The raw electronic data for quality 
controls, and specimens should be backed up electronically on a monthly basis.  
Instrument records are stored in the laboratory for the life of the instrument and off-site 
an additional 7 years. 
 
Instrument Calibration 
The performance of the Safire2™ plate reader will be evaluated every month by the BCG 
lab by using the MultiCheck-Plus test plate. All data collected is retained by the BCG lab. 
Luminescence, absorbance, and fluorescence will be evaluated. The following optical 




o precision {SD} 
o signal/blank 
• Time-Resolved Fluorescence 
o lag time check  
• Fluorescence Polarization 
o precision{SD} 
o LED verification 
• Absorbance (NIST traceable) 
o linearity 
o accuracy {bias} 




• Optical alignment for all detection modes 
• Excitation and Emission Wavelength (NIST traceable) 
o accuracy {bias} 





Quality Control  
• Two levels of controls for each sample type are available within a run: normal 
leukocytes and affected leukocytes.  See Reagent Preparation section for making 
the controls.  
• The beta-glucosidase activity must be within the defined limits.  If this 
qualification is not met, the run will be reviewed by the Medical Director prior to 
acceptance and reporting of patient results.   
 
Procedure 
Isolation of Leukocytes 




1. Gather ice in an ice bucket. 
2. Remove the tubes with the prepared white blood cell pellets from the freezer and 
place on ice.  Use only one aliquot for patient.  Retain the remaining aliquots in case 
there is a need to repeat the testing. 
3. Loosen up the cell pellet by gently flickering the tube.  
4. Remove the chilled nanopure water from the fridge and place on ice. Aliquot about 
2mL of water in a tube to wash the sonicator probe tip before use, and between 
samples. 
5. Add 500µL of chilled water (less if the pellet is very small, more if the pellet is 
large).  
6. Immerse the sonicator probe tip into the tube until it is about ½ of the distance 
between the upper meniscus and the bottom of the tube. 
7. Sonicate three times for 10 seconds at approximately 8-watt burst (Instrument setting 
of 3).  Wait 10 seconds in between rounds of sonication taking the tip out of the 
sample.             Keep the sample on ice during the sonication. 
8. Between samples, wash the probe tip in water.  
9. After sonication, quantify the protein concentration in the sample.  The protein 
amount used for the assay should be between 0.010 mg and 0.035 mg (which 
corresponds to 35uL sample and a 0.3 – 1 mg/mL protein concentration).  See section 
titled Protein Determination in Leukocytes. 
 
Protein Determination in Leukocytes 
1. Prepare a standard curve for protein determination using Protein Assay Standard II – 




of Protein assay Standard II received. Always record the BSA standard lot and its 
concentration. 
2. Label 6 microcentrifuge tubes Cal 1-6.  Pipet the appropriate amount of nanopure 
water and BSA standard or calibrator.  Vortex briefly each tube.   
3. BSA concentration in calibrator 6 is calculated based on the Protein assay Standard II 





Calibrators Concentration of BSA (mg/ml) 
µL of BSA 
or Calibrator 
µL of water 
1 0 0 100 
2 0.058 100 of Cal 3 200 
3 0.175 100 of Cal 4 50 
4 0.263 100 of Cal 5 50 
5 0.394 100 of Cal 6 50 
6 0.592 100 150 
 
When BSA standard concentration  = 1.48 mg/mL, 
The Cal 6 BSA solution conc = (1.48 mg/mL x 100 uL) / (100 uL + 150uL) 
      = 0.592 mg/mL. 
4. Label one microcentrifuge tube for each leukocyte sample.  Transfer 20µL of each 
leukocyte sonicate into the labeled tube. Add 40 uL Nanopure water. Cap the tube 
and vortex briefly to mix.   
5. Fill out a plate map, designating a calibrator, or specimen ID to wells of a clear 96-
well plate. 
6. Prepare the protein diluent in 15mL (or 50mL) conical tube 
a. Pipet 1 part Bio-Rad Protein Assay-Dye Reagent Concentrate plus 4 parts 
nanopure water as indicated in the chart below. 
# of samples 
(Patients Plus 
Calibrators) 
mL of Dye Reagent 
Concentrate 
mL of Nanopure 
water 
10 1 4 
20 2 8 





7. Pipette 10 uL of each calibrator and diluted patient leukocyte sonicates into the 
appropriate wells.  
8. Using a repeat pipette with a 5 mL tip, add 200 uL protein diluent to each sample. 
Cover the plate and place the plate on orbital shaker. Shake the plate at 150 rpm for 5 
minutes. The plate is then ready for protein measurement. 
9. Turn on TECAN Safire2 and open the software Magellan6 (All 
programs>tecan>magellan6). 
10. Choose “Start measurement” and continue. 
11. Choose “Use predefined method”, click on method Protein 20140710.mth and click 
on “make your selection”. 
12. Name Workspace with assay and date information, such as “Protein 20140620.wsp”. 
13. Place sample plate on cartridge with A1 on the upper left corner, and click on “Plate 
in” and start the run. 
14. After the measurement, in the Edit dropdown list, click on “Copy to Exel”. An Excel 
sheet should pop up.  
15. Save the data file again with the same file name. Discard the plate. 
16. Exit Magellan and turn off TECAN Safire2. 
17. Transfer data to the bGLU excel worksheet. 
 
Assay 
1. Controls  
a. Remove frozen aliquots of control samples from the freezer and place on ice to 
thaw. 
b. Remove frozen substrate from the freezer and place on ice to thaw. 
2. Set up enough PCR 8-well tube strips to accommodate all samples into the cool rack.  
3. Label each strip 1 to 12 according to the plate map. Each patient sample and control 
will require 2 wells each (i.e. 2 strips will accommodate the replicates for 8 samples). 
a. Two strips for each set of duplicate samples.  
b.Below an example of the plate map that includes six calibrators, blanks, positive 
and negative controls and 13 samples. Columns 1 to 12 represent the 8-well tube 
strips used. Calibrators are NOT added into the strips; they are added to the plate 





4. Pipet 20µL of Nanopure water in use (chilled at 4°C) in the blank wells. 
5. Pipet 20µL of the leukocyte sample or controls into each well. Briefly vortex the 
samples before adding them. 
6. Add 80 uL of the substrate prepared fresh.  
7. Cap all wells with bubble caps. Press well. 
8. Briefly vortex the strips, and then place them on the PCR. Start the HOLD37_2 
program: 120 minutes at 37.0°C, 30 seconds at 4.0°C; press yes for heated top. 
9. Incubate for 120 minutes. 
10. At the end of this 120 minutes incubation (about 10 minutes before the end), prepare 
the 4-Methylumbelliferone Standard calibration curve (See Calibration section). 
11. At the end of the 120 minutes incubation, remove all samples from the PCR, take off 
the caps (carefully, to avoid sample splashing), and stop the reaction by adding 150uL 
of GC buffer. Use a multichannel pipette. 
12. Transfer 40uL of the stopped reactions to a black microplate. Use a multichannel 
pipette, mixing samples before the transfer. Be gentle to avoid creating bubbles 
during the transfer. 
13. Add 200uL of GC buffer to all wells of the microplate. Add 240uL of each calibrator 
to the microplate.  
14. Turn on the plate reader (power button: ON).  The green light will come on. Open the 
Magellan6 program. Be careful, the plate holder will come forward automatically. Set 
the plate in, placing the A1 well to the top left corner. 
15. Read fluorescence on the Safire2 at 365 nm excitation and 441 nm emissions Select 
“start measurement”. Use the predefined method selecting the “Use Predefined 
Method” option. Select the following method: BCG HEX-A. Optimaze the Z-position 
in well A4 (using the standard 4). The program includes a brief shacking step to mix 
the samples before reading. 
16. Transfer data to the bGLU excel worksheet (EDIT>Copy to excel; copy and paste 
data into the worksheet) and analyze the run. 
17. Exit Magellan6 program and turn off the instrument. 
1 2 3 4 5 6 7 8 9 10 11 12
A Blk Blk S6 D1 S6 D2 Std. 1
B Neg Cntr D1 Neg Cntr D2 S7 D1 S7 D2 Std. 2
C Pos  Cntr D1 Pos  Cntr D2 S8 D1 S8 D2 Std. 3
D S1 D1 S1 D2 S9 D1 S9 D2 Std. 4
E S2 D1 S2 D2 S10 D1 S10 D2 Std. 5
F S3 D1 S3 D2 S11 D1 S11 D2 Std. 6
G S4 D1 S4 D2 S12 D1 S12 D2






o Excitation (EX) 365nm 
o Emission (EM) 441nm 
o Excitation wavelength fixed mode (EX WL) 
o Slit 
 EX 10.0 
 EM 10.0 
o Measurement: Photometry 
• Quantitation 
o Quantitation type = wavelength 
o Concentration nmol/mL 
o 1st order calibration 
o Force through zero 
• Standards 
o 1 = 0 
o 2 = 0.12µmol/L 
o 3 = 0.52µmol/L 
o 4 = 1.03µmol/L 
o 5 = 2.0µmol/L 
o 6 = 2.53µmol/L 
 
Acceptability of a Run 
• The beta-glucosidase activity for each control (normal and affected) must be 
within the defined limits.  If this qualification is not met, the run will be reviewed 
and, if appropriate, approved by the Medical Director prior to acceptance and 
reporting of patient results.   
• The average fluorescence reading of the duplicate samples must be within 10% 
CV.  If the CV is greater than 10%, the sample needs to be reviewed.   
 
Result Interpretation & Reporting  
The Medical Director is the sole person to interpret patient results and draw conclusions 
for specimen reporting.  Other patient sample results within the reference interval may be 
verified in the LIS by the performing technologist without Medical Director’s 







The beta-glucosidase activity is calculated for each sample: 
 
Beta-glucosidase = nanomoles of substrate hydrolyzed per hour per milligram of protein 
 
=   (fluor of total activity – fluor of blank) * 0.24   *6.25 
                                     (y)                                                    ÷ 2 ÷ (mg of protein used for 
assay)  
 
NOTE:  The above calculations based upon: 
 / 2 = correction of 120 minutes to 60 minutes 
 x 0.24 = correction to account for final concentration in samples versus 
calibrators 
                      x 6.25 = correction for final volume 
             mg of protein used for assay = 0.020*protein conc. of sonicate (mg/mL) 
 
Method Limitations 
• Pseudo-deficiency has been shown for this enzyme, due to specific mutations 
affecting the exogenous substrate used by this assay, but not endogenous 
substrates. This can result in low enzymatic activity; although usually levels are 
higher than found in Gaucher patients. 
• Enzymatic testing is not reliable for carrier detection. 
• Further differentiation in subclinical types (Gaucher disease Type I, II or III) 






No back-up procedure is in place.  If the test cannot be performed at ARUP Laboratories 
the sample will be sent out.  Contact the Technical Supervisor and/or Group Manager 
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